SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Burzynski Research Institute Inc. – ‘10-Q’ for 5/31/22 – ‘XML’

On:  Thursday, 7/14/22, at 4:15pm ET   ·   For:  5/31/22   ·   Accession #:  1558370-22-10716   ·   File #:  0-23425

Previous ‘10-Q’:  ‘10-Q’ on 1/14/22 for 11/30/21   ·   Next:  ‘10-Q’ on 10/13/22 for 8/31/22   ·   Latest:  ‘10-Q’ on 1/16/24 for 11/30/23   ·   1 Reference:  To:  Burzynski Research Institute Inc. – ‘10SB12G’ on 11/25/97

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/14/22  Burzynski Research Institute Inc. 10-Q        5/31/22   33:1.6M                                   Toppan Merrill Bridge/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    450K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     16K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     17K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     13K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     13K 
11: R1          Document and Entity Information                     HTML     66K 
12: R2          Balance Sheets                                      HTML     70K 
13: R3          Balance Sheets (Parenthetical)                      HTML     20K 
14: R4          Statements of Operations                            HTML     52K 
15: R5          Statements of Stockholders' Equity (Deficit)        HTML     32K 
16: R6          Statements of Cash Flows                            HTML     44K 
17: R7          Basis of Presentation                               HTML     18K 
18: R8          Economic Dependency                                 HTML     21K 
19: R9          Stock Options and Warrants                          HTML     25K 
20: R10         Loss Per Common Share                               HTML     15K 
21: R11         Income Taxes                                        HTML     33K 
22: R12         Stock Options and Warrants (Tables)                 HTML     19K 
23: R13         Income Taxes (Tables)                               HTML     27K 
24: R14         Basis of Presentation (Details)                     HTML     15K 
25: R15         Stock Options and Warrants (Details)                HTML     49K 
26: R16         Loss Per Common Share (Details)                     HTML     13K 
27: R17         Income Taxes (Details)                              HTML     43K 
28: R18         Income Taxes - Operating Loss Carryforwards         HTML     25K 
                (Details)                                                        
31: XML         IDEA XML File -- Filing Summary                      XML     47K 
29: XML         XBRL Instance -- bzyr-20220531x10q_htm               XML    229K 
30: EXCEL       IDEA Workbook of Financial Reports                  XLSX     35K 
 7: EX-101.CAL  XBRL Calculations -- bzyr-20220531_cal               XML     49K 
 8: EX-101.DEF  XBRL Definitions -- bzyr-20220531_def                XML    123K 
 9: EX-101.LAB  XBRL Labels -- bzyr-20220531_lab                     XML    376K 
10: EX-101.PRE  XBRL Presentations -- bzyr-20220531_pre              XML    225K 
 6: EX-101.SCH  XBRL Schema -- bzyr-20220531                         XSD     59K 
32: JSON        XBRL Instance as JSON Data -- MetaLinks              129±   189K 
33: ZIP         XBRL Zipped Folder -- 0001558370-22-010716-xbrl      Zip    102K

‘XML’   —   XBRL Instance — bzyr-20220531x10q_htm

This Document is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bzyr="http://www.burzynskiresearch.com/20220531" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="bzyr-20220531.xsd" xlink:type="simple"/>
<context id="Duration_3_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_11fQr4xt_UOobBNrBjov3A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-05-31 </endDate>
</period>
</context>
<context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EACuDqjci0eOu6MrAist4Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-05-31 </instant>
</period>
</context>
<context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DY1rJAmkcU2GgmNxmMNF0w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dTcaV_F13EyB-aSqzGRYxw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-02-28 </instant>
</period>
</context>
<context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8RriA2Uq00ifttLgiW9RZA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-02-28 </instant>
</period>
</context>
<context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nvEmPZuW2USE-ybQxBPFWQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-05-31 </instant>
</period>
</context>
<context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vJLZDFtjNkuAtIHb_WeOpg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5y6HJabJbEK3Fjy3GTGlsw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-02-28 </instant>
</period>
</context>
<context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yQ1jyexUG0Wdcp6LUz9ohw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-02-28 </instant>
</period>
</context>
<context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__BCHLS8TMkWBQRjcaAb9uw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G-1Lq6JUzkKmeNRq_ZFngg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-02-28 </instant>
</period>
</context>
<context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RzXIPhnYEyp0paEr3zV4A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RordQiOIW0mmuvypCou0nw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-02-28 </instant>
</period>
</context>
<context id="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_d0PY-pZfSUuDYWLeHVMA8g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 1998-06-01 </startDate>
<endDate> 1998-06-01 </endDate>
</period>
</context>
<context id="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pWGnfQrVh0u34suChi0QNg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 1997-06-01 </startDate>
<endDate> 1997-06-01 </endDate>
</period>
</context>
<context id="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_reKon-M4okGZb09B4rZvmg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 1996-09-14 </startDate>
<endDate> 1996-09-14 </endDate>
</period>
</context>
<context id="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BUckO3awlk2p_gF7xInW9Q">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BxKMuu-MfUinOkShasA--w">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-05-31 </endDate>
</period>
</context>
<context id="As_Of_5_31_2021_Dmclhm-6rEuY-xr1cO2kpg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2021-05-31 </instant>
</period>
</context>
<context id="As_Of_2_28_2021_7PtXRYv_WkakPZ0_peyMpA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2021-02-28 </instant>
</period>
</context>
<context id="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2022-02-28 </instant>
</period>
</context>
<context id="As_Of_6_30_2022_Lxa8VthgpUepZ3ZF4BtTXQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_zYS5bIyq2UWg1EJ6XBv_9g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2012-07-05 </instant>
</period>
</context>
<context id="As_Of_5_31_2022_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember_7cYU9yyB0kuXZEOaAfyHBQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis"> us-gaap:LatestTaxYearMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-05-31 </instant>
</period>
</context>
<context id="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<instant> 2022-05-31 </instant>
</period>
</context>
<context id="Duration_3_1_2022_To_5_31_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_2aofZ6oDoEaxnXJ8h8HwlQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementScenarioAxis"> bzyr:HundredPercentFutureTaxableIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2022_To_5_31_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_H7HmrsWwVEefSyrOMp17qw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementScenarioAxis"> bzyr:EightyPercentFutureTaxableIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2022_To_5_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_GjIKL_5ks0WcLVFPqicHIA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:InternalRevenueServiceIRSMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-05-31 </endDate>
</period>
</context>
<context id="As_Of_5_31_2022_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_GqEGaxjDKEWGPEbJcqTK5g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-05-31 </instant>
</period>
</context>
<context id="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_YoAv_Pd_uUawMfqQ7u6BgA">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2012-07-05 </startDate>
<endDate> 2012-07-05 </endDate>
</period>
</context>
<context id="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-BoC4sMqUG0IbiFwvQw9g">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sz3L4QBG10O-5wAn5Khl2A">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-05-31 </endDate>
</period>
</context>
<context id="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000724445 </identifier>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-05-31 </endDate>
</period>
</context>
<unit id="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA">
<measure> iso4217:USD </measure>
</unit>
<unit id="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ">
<measure> shares </measure>
</unit>
<unit id="Unit_Standard_item_sqywRvE1-UKcREfsEGH_Wg">
<measure> bzyr:item </measure>
</unit>
<unit id="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw">
<measure> pure </measure>
</unit>
<unit id="Unit_Divide_USD_item_nfCQyOpafke6QgvyWaf-Fg">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> bzyr:item </measure>
</unitDenominator>
</divide>
</unit>
<unit id="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> shares </measure>
</unitDenominator>
</divide>
</unit>
<us-gaap:CommitmentsAndContingencies contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" id="Hidden_n3jI692SuUaMA13WrgxZbA" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" id="Hidden_RZyKNuE4x0CG3qUBbN6eiQ" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA" xsi:nil="true"/>
<dei:EntityRegistrantName contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Hidden_aye9xOM8SECG-iqLX3JmTw"> BURZYNSKI RESEARCH INSTITUTE INC </dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_PICqbLGvl0yGm8G80lVICA_2_1"> 0000724445 </dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_UzIp6bszm0C3PMprWAf4Wg_3_1"> --02-28 </dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalYearFocus contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_rh5ufa-PNkuCAAXEMPC9Og_4_1"> 2023 </dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_b6rzYGX3hU-3OrLMn-KuGg_5_1"> Q1 </dei:DocumentFiscalPeriodFocus>
<dei:AmendmentFlag contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_dtJ57jYStU2BV3fWXV3lhQ_6_1"> false </dei:AmendmentFlag>
<us-gaap:EarningsPerShareBasic contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="2" id="Hidden_mRfY4h5U_kC9alhlAfUmIA" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.00 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="2" id="Hidden_Em4LwFLzdESTxU6f2awexw" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.00 </us-gaap:EarningsPerShareBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Hidden_szwPzeGFk0Cmay_WA4RFAQ" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Hidden_xO_7BuCdw0my5yRZuPbDvA" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<dei:SecurityExchangeName contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Hidden_57m841YoXUm9wddTjFEDXA"> NONE </dei:SecurityExchangeName>
<us-gaap:CommonStockSharesOutstanding contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="INF" id="Hidden_XvBNnS9ShEGa4k2cXjcYyg" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="INF" id="Hidden_oAzf45GuAU6goshuPI68EQ" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<dei:DocumentType contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_pij9JkKJHE2fv59nGidwQw"> 10-Q </dei:DocumentType>
<dei:DocumentQuarterlyReport contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_IPfR-Mk_W0KVzz7sNqyQGg_1_0"> true </dei:DocumentQuarterlyReport>
<dei:DocumentPeriodEndDate contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_Oo2dKpNFFEedq2w6iUFlHA"> 2022-05-31 </dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_kJf8DFgiIkCDuFNQ12VMUQ_1_0"> false </dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_jPWx414L80KV-P9H3zFlVQ"> 000-23425 </dei:EntityFileNumber>
<dei:EntityIncorporationStateCountryCode contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_iUAz5VtcdkO7c-tZH70DzQ_1_0"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_L_S3t6zKREyDrHSzKsBtwQ_1_2"> 76-0136810 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_FscBfoDhyUintXJMU_cJJQ"> 9432 Katy Freeway </dei:EntityAddressAddressLine1>
<dei:EntityAddressAddressLine2 contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_P8MWSl-w70G2lKSBKKCC0A"> Suite 200 </dei:EntityAddressAddressLine2>
<dei:EntityAddressCityOrTown contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_M6iMuI16SUqtqNFDzKrgsw"> Houston </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_WIn0uIWfcUCogz8bc80rHg"> TX </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_kUQBij6W6UyLzVw4rqzcNA"> 77055 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_XXTPDG_yoU6vxy_4W8n2sA"> 713 </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_Ysoizn1lD0W3GO6B3fU5Ew"> 335-5697 </dei:LocalPhoneNumber>
<dei:Security12bTitle contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_AtbFCGkRYUKAbFESW78olA_2_0"> None </dei:Security12bTitle>
<dei:TradingSymbol contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tc_k2-34Ai6WUiB4GT5C7TFXA_2_2"> BZYR </dei:TradingSymbol>
<dei:EntityCurrentReportingStatus contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_4GQomgsGnEy3thQqFXqXug"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_vufey_HxxEelF4RTB0oYmg"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_agb3LI5LxE2kw1t_t2I_PQ"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_yCEwioqWS0GkjBZfA-IF8A"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_WDIGUHBnzEmgZDJipMVM5g"> false </dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Narr_jl4hno7S-EOjf8IaYr_aZw"> false </dei:EntityShellCompany>
<dei:EntityCommonStockSharesOutstanding contextRef="As_Of_6_30_2022_Lxa8VthgpUepZ3ZF4BtTXQ" decimals="INF" id="Narr_8st4JLPCQEqrYMwqfyO0lA" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_NYzyC0OgzEK6Ht7K358e5g_6_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 4766 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_cLnxG3IP9kGswih45TzghQ_6_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 3382 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_RljVhkMBZEmcZup87f4vDw_7_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 700 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_2ylFvL9CxEyp6v2BRT2xqw_7_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 1279 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_r1QTgsCUxkSZSkiRiHfghw_9_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 5466 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_pxoU3epy3USn5qJTtPBhFQ_9_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 4661 </us-gaap:AssetsCurrent>
<us-gaap:Assets contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_gab_iLaEVEap7xNzcjNOkg_11_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 5466 </us-gaap:Assets>
<us-gaap:Assets contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_rC_UxLhkG0KtzpA-aR__pA_11_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 4661 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_zJIRkz9JO0OylnhfFg-n9Q_16_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 13925 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_rLaHv_5sDUeuCPaP0eto4g_17_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 30221 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_Ajl8lF16I0uWvembUb0isQ_17_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 3455 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:Liabilities contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_LszBXm-PRkSSp-w0XryeCg_19_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 44146 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_qT3TWzz-Yk6j6WfPgVKCEw_19_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 3455 </us-gaap:Liabilities>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="INF" id="Narr__Lr13Dz1rUWKS4QcZws6xg" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="INF" id="Narr_4U7psap4J0y3tYn3SvSfew" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="INF" id="Narr_jS-7zHVkw0G3v5hvqyzGcg" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="INF" id="Narr_Z1udDOMFlEaUZcWKZRzv_A" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="INF" id="Narr_0xXLE12YNEa9TYA6FpZHbw" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="INF" id="Narr_LGIDisTZtEiOmLiNGP6G0A" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockValue contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_K5CzHGpIUEu2mRphEDGzmg_24_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 131449 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_j5s08E3_2EC3NU0PgffYmw_24_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 131449 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_lzxtKBBALEa63hbemyeWig_25_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 125900091 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_2RKKn3MT-UebHlOVIz0rSw_25_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 125708240 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_uuPA8UD1ZEqAWpAsC673hw_26_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -126070220 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_LJjSgKfZmkGbFW4tNDC8zw_26_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -125838483 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_E6Swm8DT0Ua1Qo6XVGCn9g_28_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -38680 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_AggW1sGgS0GjMau05a1UvQ_28_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 1206 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_GcgLSOFJ1E66hX-sgdSYDQ_30_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 5466 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_5AWTCBaiRE6GzOr2Zoayeg_30_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 4661 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_9PpgEJ4wrkevlu5jhK_L7g_4_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 167354 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_4rhV-py-r0K45m8TaS91JQ_4_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 231946 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc__F25TrIUi0qO_aQbLbzZCQ_5_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 64383 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc__aPnCbqWRE2v69ePPDlRrA_5_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 84337 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_sFptyf6XVkG17L6KmnFfYw_7_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 231737 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_KVoGqknBV0iTqc0HjLZYrQ_7_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 316283 </us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_iH8taIYEw0Otc5Qx5apmNg_9_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -231737 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_6mkLHWlbvkWHeyakKDdm-g_9_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -316283 </us-gaap:OperatingIncomeLoss>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_-wA1EANBPEeqgpvkCqOx-w_11_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -231737 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_cUgO0Okk4USppkJgw6889Q_11_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -316283 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_jImygb1eMkWIMSDF0UkT7A_13_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -231737 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_UGg0qCMGdUuX_DgxSUgq3g_13_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -316283 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareDiluted contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="2" id="Tc_rw49aPK5AEOXnzhizKTUTA_17_3" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.00 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="2" id="Tc_aRybK8i5IEyIV0N6GroSeg_17_6" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.00 </us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_oEbHMXZjHUaM6TwKv6KrOQ_19_3" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_BmF0AMUDBUGNlxxPLLIMbA_19_6" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:SharesOutstanding contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G-1Lq6JUzkKmeNRq_ZFngg" decimals="INF" id="Tc_nd2E8xup5UqgyyduTr7S9g_4_2" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G-1Lq6JUzkKmeNRq_ZFngg" decimals="0" id="Tc__AYGDD4JCkGD9kNxy2Mw5g_4_5" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8RriA2Uq00ifttLgiW9RZA" decimals="0" id="Tc_pzuY-9BMb0ud_YcQWFjjxw_4_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 125708240 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dTcaV_F13EyB-aSqzGRYxw" decimals="0" id="Tc_cdFQFj04G0qXg_pVcV8EwA_4_11" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -125838483 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_hSwb1IKFLUqLrfi9Jlq-0g_4_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 1206 </us-gaap:StockholdersEquity>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-BoC4sMqUG0IbiFwvQw9g" decimals="0" id="Tc_ZlkvNP__V0iJitak18B-fw_6_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 40517 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_pFkazpN8LkucNmvuwhQUmQ_6_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 40517 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-BoC4sMqUG0IbiFwvQw9g" decimals="0" id="Tc_pIgc13uIcE-nyPd5Wckkpg_8_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 151334 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_L8RbZGg6LkC1UbQqz9YrVg_8_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 151334 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BUckO3awlk2p_gF7xInW9Q" decimals="0" id="Tc_xm9zoLKAFk2WYyJgnC3XLw_10_11" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -231737 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_M3fvfEyUe0SOleEO3iAlaw_10_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -231737 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:SharesOutstanding contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__BCHLS8TMkWBQRjcaAb9uw" decimals="INF" id="Tc_6Dli6HXY-ES6jso1L2rtSw_12_2" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__BCHLS8TMkWBQRjcaAb9uw" decimals="0" id="Tc_UaDs_ot-kkqJsdmZEH6dQQ_12_5" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DY1rJAmkcU2GgmNxmMNF0w" decimals="0" id="Tc_zXgAYTx7PkKYwmXGD7P6_A_12_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 125900091 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EACuDqjci0eOu6MrAist4Q" decimals="0" id="Tc_NdE0CN2HbkaIBzOo4i_cag_12_11" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -126070220 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_be-DVA4MnESL2RmBz70Iqg_12_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -38680 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RordQiOIW0mmuvypCou0nw" decimals="INF" id="Tc_NWPre58S7kCZuq7gxW2UGA_4_2" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RordQiOIW0mmuvypCou0nw" decimals="0" id="Tc_aro5oavR-EuhBgEJ3dtD_Q_4_5" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yQ1jyexUG0Wdcp6LUz9ohw" decimals="0" id="Tc_dosfP4B3ok6dtRtX385n_Q_4_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 124684535 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5y6HJabJbEK3Fjy3GTGlsw" decimals="0" id="Tc_SzVNbk5NdkG59Af7KBOliw_4_11" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -124861827 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_7PtXRYv_WkakPZ0_peyMpA" decimals="0" id="Tc_RRXti4NSH0CEOCDpQVELrw_4_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -45843 </us-gaap:StockholdersEquity>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sz3L4QBG10O-5wAn5Khl2A" decimals="0" id="Tc_-Q-sXCaCH0ODjAKDJgjvxw_6_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 84967 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_HcvjJCZcfUeCSn_7F8xwcQ_6_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 84967 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sz3L4QBG10O-5wAn5Khl2A" decimals="0" id="Tc_i-7P7tcRIUGtCd5d8QqHUw_8_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 215926 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_6Ga5oPLMk0WfwYZ_hJ50uQ_8_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 215926 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BxKMuu-MfUinOkShasA--w" decimals="0" id="Tc_stvlWFjF1E2mYwnJR1omDg_10_11" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -316283 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_xfsNkZwdokqeSFIkUGwwoA_10_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -316283 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:SharesOutstanding contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RzXIPhnYEyp0paEr3zV4A" decimals="INF" id="Tc_OCf2MIuwu0CSRRe2e6YJUg_12_2" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RzXIPhnYEyp0paEr3zV4A" decimals="0" id="Tc_GIhYsydKRkCnweShz9Y8Iw_12_5" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vJLZDFtjNkuAtIHb_WeOpg" decimals="0" id="Tc_Zt5MbVnZ2kuXKkY8X32wtQ_12_8" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 124985428 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nvEmPZuW2USE-ybQxBPFWQ" decimals="0" id="Tc_3cwz5W8XsU2_zcmY0dLvUA_12_11" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -125178110 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_Dmclhm-6rEuY-xr1cO2kpg" decimals="0" id="Tc_lE2Tu_oO3U2G1-9mixjYaQ_12_14" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -61233 </us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_ChSZl6tKh0OILVDUkuOUHQ_4_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -231737 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_pzApkSfgXkKlAvv-cLMSxw_4_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -316283 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<bzyr:ClinicalTrialExpensesPaid contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_jBRH7uzdQEiH9FC6oYx3Og_6_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 151334 </bzyr:ClinicalTrialExpensesPaid>
<bzyr:ClinicalTrialExpensesPaid contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_MWrFiSSVGkSZMEixaSwvMQ_6_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 215926 </bzyr:ClinicalTrialExpensesPaid>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_hsX4dnsI90u8RAi5snwepg_9_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -579 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_YijIXz9AoEmQkaDKglrtHw_9_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 521 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_CbySE3WfM0-TEigFpHc5RA_10_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 13925 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_xo5Psd1s_U6DAsLLZAGhrA_10_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -2071 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_7kV7eak0zEeUkeVeWjNIow_11_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 26766 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_LVecVzKKr0iu5uB74DVclA_11_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 18514 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_1mVe9hwWm0-9V0AvuWcUHA_13_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -39133 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_vYWwXaKPaUe0VeT1lJD4HA_13_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -84435 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromContributedCapital contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_2j4mVozdt0u_93futCWYiA_16_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 40517 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:ProceedsFromContributedCapital contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_zheeq-UCs0K19kl226gPBA_16_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 84967 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_S91L9A9N7UqwOlWxgkiiiw_18_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 40517 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_M8R8A-ayg0afzMYHUmmI6Q_18_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 84967 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_R74ZqoYhgEKJg5UTocatEw_20_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 1384 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_XFfRcvha0kurNGaJ94JCUQ_20_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 532 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_2_28_2022_QjjX9nKmt0uIYUFqod7wvQ" decimals="0" id="Tc_bs_REm0640Ctcq9XOTnA2g_22_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 3382 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_2_28_2021_7PtXRYv_WkakPZ0_peyMpA" decimals="0" id="Tc_aJO_C6XF602uZXjUeS16-w_22_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 62 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Tc_vO6L4TnuYEG1V9qzkW0hng_24_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 4766 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_5_31_2021_Dmclhm-6rEuY-xr1cO2kpg" decimals="0" id="Tc_HEFkUB6zdkeHK6o8cXNF_Q_24_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 594 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tb_3B6jBi3kv06TpvyyX2ve8Q">
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE A.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">BASIS OF PRESENTATION</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The financial statements of Burzynski Research Institute, <span style="white-space:pre-wrap;">Inc. (the “Company”), a Delaware corporation, include expenses incurred related to clinical trials, which were sanctioned by the U.S. Food and Drug Administration (FDA) in 1993, for Antineoplaston drugs used in the treatment of cancer. These expenses are incurred directly by S.R. Burzynski, M.D., Ph.D. (Dr. </span><span style="white-space:pre-wrap;">Burzynski or “SRB”) on behalf of the Company and have been reported as research and development costs and as additional paid-in capital. Other funds received from Dr. </span><span style="white-space:pre-wrap;">Burzynski have also been reported as additional paid-in capital. Expenses related to Dr. </span><span style="white-space:pre-wrap;">Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements. Dr. Burzynski is the President, Chairman of the Board and owner of approximately </span>81.0% of the outstanding common stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons.” </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company and Dr. Burzynski have entered into various agreements as further described in Note B. The License Agreement between the Company and Dr. Burzynski provided the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once the drug is approved for sale by the FDA. On July 2, 2019, the License Agreement terminated upon the expiration of the last patent licensed to the Company under such agreement. As such, the Company does not currently own any patents or have licenses to any patents with respect to Antineoplastons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer. The Company’s investigational new drug application (“IND”) 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of May 31, 2022 and February 28, 2022, results of operations for the three months ended May 31, 2022 and 2021, and cash flows for the three months ended May 31, 2022 and 2021. All adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022.</span></p>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="3" id="Narr_uDDn11NdfUGU3Vt-A97SDg" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.810 </bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard>
<bzyr:NumberOfAntineoplastonDrugsThatReceivedFDAApproval contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="INF" id="Narr_4vVx0vjAcEWmJS3rWiN8Wg" unitRef="Unit_Standard_item_sqywRvE1-UKcREfsEGH_Wg"> 0 </bzyr:NumberOfAntineoplastonDrugsThatReceivedFDAApproval>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tb_pdpSlNDo8EisHHe8vrwP9Q">
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE B.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">ECONOMIC DEPENDENCY</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit. Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</span> Because the Company is entirely dependent upon the contributions for research provided by Dr. Burzynski under a research funding agreement, the Company would not be able to continue conducting its clinical trials if Dr. Burzynski ceased funding the Company’s research. In such event, the Company would be required to find immediate funding which may not be available on acceptable terms or at all. If this were to occur and the Company were not able to find adequate sources of funding, the Company would be required to cease operations. Even with Dr. Burzynski’s continued contributions under a research funding agreement, the Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company. In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice. In the past, a portion of Dr. Burzynski’s patients have been admitted and treated as part of the clinical trial programs. The Company’s IND 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA. These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA. In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</span></p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tb_qnseB5GZ30uKNzvHJsknYQ">
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE C.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">STOCK OPTIONS AND WARRANTS</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At May 31, 2022, the Company had one stock-based employee compensation plan, which is described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35<span style="white-space:pre-wrap;"> per share, to an officer who is no longer with the Company. </span>The options vested as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 14, 1996</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1997</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1998</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The options are valid in perpetuity. </span>None of the options have been exercised as of May 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for share-based payments to non-employees in accordance with the guidance provided by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, <i style="font-style:italic;">Compensation – Stock Compensation</i> to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;">Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to </span><span style="font-size:10pt;">10%</span><span style="font-size:10pt;"> of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of </span><span style="font-size:10pt;">2,000,000</span><span style="font-size:10pt;"> shares of the Company’s Common Stock, exercisable at </span><span style="font-size:10pt;">$0.10</span><span style="font-size:10pt;"> per share with a </span><span style="font-size:10pt;">ten year</span><span style="font-size:10pt;"> exercise period, with </span><span style="font-size:10pt;">1,000,000</span><span style="font-size:10pt;"> shares vesting upon execution of the agreement (the "Initial Warrants") and the remaining </span><span style="font-size:10pt;">1,000,000</span><span style="font-size:10pt;"> shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. The fair market value of the vested warrants as of the date of grant was measured using the Black-Scholes option pricing model and totaled approximately </span><span style="font-size:10pt;">$160,000</span><span style="font-size:10pt;"> or </span><span style="font-size:10pt;">$0.16</span><span style="font-size:10pt;"> per warrant. The Marketing Agreement was terminated effective as of July 5, 2019 pursuant to its terms. The Initial Warrants are currently outstanding and can still be exercised. As of May 31, 2022, </span><span style="font-size:10pt;">none</span><span style="font-size:10pt;"> of the aforementioned vested warrants have been exercised.</span></p>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="INF" id="Narr_FtBb88Ym7UewwaQk-fC1tQ" unitRef="Unit_Standard_item_sqywRvE1-UKcREfsEGH_Wg"> 1 </bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_reKon-M4okGZb09B4rZvmg" decimals="INF" id="Narr_puQNeBZX3kaKGLysi6F45w" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 600000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_reKon-M4okGZb09B4rZvmg" decimals="2" id="Narr_eTc-0ZLvYUSgkKL6eJLVPA" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.35 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tb_3B3DWhNEBkCYL72OHnxVmQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 14, 1996</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1997</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1998</p></td></tr></table>
</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_reKon-M4okGZb09B4rZvmg" decimals="INF" id="Tc_8GdwvMXvHEqSmeyzgKqI1A_2_0" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 400000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pWGnfQrVh0u34suChi0QNg" decimals="INF" id="Tc_xxtq08hk1E6-RcHzoP_g1A_3_0" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 100000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_d0PY-pZfSUuDYWLeHVMA8g" decimals="INF" id="Tc_HjKoneRrTEyLGVNpI3bCcg_4_0" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 100000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_11fQr4xt_UOobBNrBjov3A" decimals="INF" id="Narr_xFqwXeVO2E6E8PQEeIrkLw" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_YoAv_Pd_uUawMfqQ7u6BgA" decimals="2" id="Narr_ydqg7i35-k2uDSmevIqtaQ" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.10 </bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_zYS5bIyq2UWg1EJ6XBv_9g" decimals="INF" id="Narr_VezSWMsg1kKEX6I93GK_sQ" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 2000000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_zYS5bIyq2UWg1EJ6XBv_9g" decimals="2" id="Narr_3pfkKc360UOgvYTZtmdRXA" unitRef="Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q"> 0.10 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<bzyr:ClassOfWarrantOrRightsExercisePeriod contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_YoAv_Pd_uUawMfqQ7u6BgA" id="Narr_-GJnqFfDHECApGhwbfIG7A"> P10Y </bzyr:ClassOfWarrantOrRightsExercisePeriod>
<bzyr:SharesVestingUponExecutionOfAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_YoAv_Pd_uUawMfqQ7u6BgA" decimals="INF" id="Narr_I4CFWsTAykqPx3U_GabMgg" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 1000000 </bzyr:SharesVestingUponExecutionOfAgreement>
<bzyr:RemainingSharesToVestUponFirstClosingOfAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_YoAv_Pd_uUawMfqQ7u6BgA" decimals="INF" id="Narr_qM4m5uEhskaXAh9tsuDNHQ" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 1000000 </bzyr:RemainingSharesToVestUponFirstClosingOfAgreement>
<us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_zYS5bIyq2UWg1EJ6XBv_9g" decimals="0" id="Narr_JzkLrnWRJUmpNftf90jhng" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 160000 </us-gaap:WarrantsAndRightsOutstanding>
<bzyr:WarrantOrRightFairValuePerWarrant contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_zYS5bIyq2UWg1EJ6XBv_9g" decimals="2" id="Narr_RpM_hf9b0EGaRfJLJvIYsw" unitRef="Unit_Divide_USD_item_nfCQyOpafke6QgvyWaf-Fg"> 0.16 </bzyr:WarrantOrRightFairValuePerWarrant>
<bzyr:ClassOfWarrantOrRightsWarrantsExercisedNumber contextRef="As_Of_5_31_2022_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_GqEGaxjDKEWGPEbJcqTK5g" decimals="INF" id="Narr_-I3jmnR_n0yGeIkRBu79TA" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 0 </bzyr:ClassOfWarrantOrRightsWarrantsExercisedNumber>
<us-gaap:EarningsPerShareTextBlock contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tb_yICluLwTpUKwCwCiZreW7Q">
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE D.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">LOSS PER COMMON SHARE</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for loss per share in accordance with FASB ASC 260, <i style="font-style:italic;">Earnings per Share</i>. Basic loss per share amounts are calculated by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the periods, including the dilutive effect of all common stock equivalents. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported. During the three months ended May 31, 2022 and 2021, 1,600,000 warrants and stock options were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.</p>
</us-gaap:EarningsPerShareTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="INF" id="Narr_ELk8sVqROkeUgYz58bPFQg" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 1600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="INF" id="Narr_KJCePBlhEUm02q34zjVycA" unitRef="Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ"> 1600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tb_JgBShyHVtU-19J5v9vHljw">
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE E.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">INCOME TAXES</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company follows the provisions of FASB ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">. The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;white-space:pre-wrap;">The federal income tax returns of the Company for 2020, 2019, and 2018 are subject to examination by the IRS, generally for </span><span style="font-size:10pt;">three years</span><span style="font-size:10pt;"> after they are filed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The actual provision for income tax for the three months ended May 31, 2022 and 2021 differ from the amounts computed by applying the U.S. federal income tax rate of 21% to the pretax loss as a result of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended May 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (66,419)</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,419</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,232</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,376)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,232)</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At May 31, 2022, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $167,078<span style="white-space:pre-wrap;">. The Company’s ability to utilize net operating loss ("NOL") carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income. The Company has </span>no<span style="white-space:pre-wrap;"> historical earnings on which to base an expectation of future taxable income. Accordingly, a full valuation allowance for deferred tax assets has been provided.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As a result of the Tax Cuts and Jobs Act of 2017 (the "Act"), NOL carryforwards generated in years beginning after December 31, 2017, would carryforward indefinitely, and would apply to 80% of future taxable income. Under the Act, carrybacks of NOLs were disallowed. In March 2020, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act was enacted providing a five-year carryback for losses incurred in 2018, 2019, or 2020, which allows companies to modify tax returns up to five years prior to offset taxable income from those tax years. The CARES Act also temporarily suspended the NOL limit of 80%<span style="white-space:pre-wrap;"> of taxable income through December 31, 2020, but the NOLs generated in 2018 and forward would still carryforward indefinitely. Effective January 1, 2021, NOL carryforwards generated will only apply to </span>80% of future taxable income according to the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As of May 31, 2022, the Company has net operating loss carryforwards in the amount of $473,902 that will expire between 2026 and 2038, and $118,834 that will carryforward indefinitely, of which $78,948 applies to 100% of future taxable income and $39,886 applies to 80% of future taxable income.</p>
</us-gaap:IncomeTaxDisclosureTextBlock>
<bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_GjIKL_5ks0WcLVFPqicHIA" id="Narr_0jlJGIrZLE-jiYTbBjnX6g"> P3Y </bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="2" id="Narr_ssFIN504EUC39PE1wOZ3BA" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.21 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="2" id="Narr_nsvPrkB3Sk-vC750A5HrNw" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.21 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" id="Tb_8cKLOkKQ7EamRH59eCBFpQ">
<p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended May 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (66,419)</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,419</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,232</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,376)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,232)</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p>
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_33Wa3wxEp02qyzKIC5T7tw_3_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -48665 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_EYmJBpswl0Ga-4-KUceJMQ_3_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -66419 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_4GpFtDVsk0CTVag5G0NUIw_4_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 48665 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_jZWJrXldS0WDmy3byixdyw_4_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 66419 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_wAPOzOw9hkK4qA_CKOI8IA_5_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 8376 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_JO3EgCZQ20qxuA_cpzGpYQ_5_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 3232 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Tc_eryEu0wQG0a5e-C0e-I_AA_6_3" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -8376 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_3_1_2021_To_5_31_2021_MNa-nxYO0U27AM-BrEIusQ" decimals="0" id="Tc_rfRJz2RQ4EqwIWLEaVF5BA_6_6" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> -3232 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsNet contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Narr_lAHS12BmRUGy380BHvfwvQ" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 0 </us-gaap:DeferredTaxAssetsNet>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg" decimals="0" id="Narr_RBLlwyJBmUSqQ2PyL3mCvA" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 167078 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:Revenues contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Narr_b0GpXTBZDkOcl19KYIJmRQ" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 0 </us-gaap:Revenues>
<bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="2" id="Narr_2fwIpm1V0EiARrOXJ-TsGA" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.80 </bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards>
<bzyr:PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="2" id="Narr_tcq0IpsfAU-oGlvqZPfiBA" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.80 </bzyr:PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct>
<bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="2" id="Narr_S5SsQTzocE2bu2K5Yr3ZlA" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.80 </bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards>
<bzyr:TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards contextRef="As_Of_5_31_2022_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember_7cYU9yyB0kuXZEOaAfyHBQ" decimals="0" id="Narr_2nV_d3gkCUGbLcv950d6xQ" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 473902 </bzyr:TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards>
<bzyr:NetOperatingLossCarryForwardIndefinitely contextRef="Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw" decimals="0" id="Narr_9iwZKM4qWEKuHqFr4n1Vzw" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 118834 </bzyr:NetOperatingLossCarryForwardIndefinitely>
<bzyr:NetOperatingLossCarryForwardIndefinitely contextRef="Duration_3_1_2022_To_5_31_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_2aofZ6oDoEaxnXJ8h8HwlQ" decimals="0" id="Narr_L2Cn_0qU0keiaQ6RrAzDXQ" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 78948 </bzyr:NetOperatingLossCarryForwardIndefinitely>
<bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_5_31_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_2aofZ6oDoEaxnXJ8h8HwlQ" decimals="2" id="Narr_VRctdjfOEEeKD3K7KmOsfg" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 1 </bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards>
<bzyr:NetOperatingLossCarryForwardIndefinitely contextRef="Duration_3_1_2022_To_5_31_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_H7HmrsWwVEefSyrOMp17qw" decimals="0" id="Narr_vnKpLC2iGESfpTkjvxBzhg" unitRef="Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA"> 39886 </bzyr:NetOperatingLossCarryForwardIndefinitely>
<bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_5_31_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_H7HmrsWwVEefSyrOMp17qw" decimals="2" id="Narr_tlZioTIJPk-eItN-pykh6w" unitRef="Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw"> 0.80 </bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards>
</xbrl>

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/25/97  Burzynski Research Institute Inc. 10SB12G               12:196K                                   Scott Printing Co… 01/FA
↑Top
Filing Submission 0001558370-22-010716   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., May 4, 11:41:12.1am ET